Lupin reported a strong third quarter performance. Its revenue increased by 28% to ₹7,167 crore from ₹5,618.6 crore in the previous year. Its margins expanded to 31.6% from 21.5% in the previous year.

Lupin Share Price Target: A key focus area for Lupin remains its US business, which the company expects to strengthen further. Management indicated that US revenues are likely to exceed USD 1 billion ...

Stocks to BUY, SELL or HOLD Today: Brokerages recommend BUY on L&T and AB Capital, while suggesting NEUTRAL on Lupin, based on growth outlook, valuations and segment performance ...

Single-day regimen of palonosetron (PALO) and dexamethasone (DEX) for the prevention of emesis associated with moderately emetogenic chemotherapy (MEC): Subgroup analysis from a randomized phase III ...

Axis Securities has named Lupin, Aurobindo Pharma, Max, and Fortis as top picks, citing strong fundamentals, resilient growth drivers, and robust operational execution ...

FDA approval of Filkri expands Accord’s G-CSF biosimilar portfolio, offering a short-acting option for neutropenia in cancer care.

Lupin expects to maintain US sales at around $1 billion over the next two years, supported by a steady stream of new product launches. The company has several launches lined up across injectables, ...

The FDA has approved Filkri (filgrastim-laha), a biosimilar to Neupogen (filgrastim), for use in cancer patients at risk of infection due to chemotherapy. Filkri is indicated for patients receiving ...

The approval of FILKRI marks the sixth product in Accord BioPharma's growing portfolio of FDA-approved biosimilars, following the company's acquisition last year of UDENYCA ® (pegfilgrastim-cbqv), a ...

Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.